MAR 31, 2020 9:00 AM PDT

Impact of liquid biopsy in advanced HER2+ breast cancer tumors: a follow-up study

Speaker
  • Post-Doctoral Fellow
    Biography
      Dr. Allegretti has devoted his entire training and career to cancer research, initially focusing on hematological malignancies before transitioning to solid tumors. He began his career at the Sapienza University of Rome working on human NK cells. After obtaining a Bachelor's degree in Biotechnology, he moved on to another lab within the same University where he worked on different translational studies with targeted agents, which reinforced his interest in oncology. Since getting a PhD degree in 2015, he added experiences in managing primary samples, cells and different types of molecular and cellular biology techniques through his internship. Two years later at the end of 2017, he moved to IRCCS Regina Elena National Cancer Institute where he led studies on monoclonal antibodies against the HER2 receptor by developing innovative liquid biopsy workflows from scratch. Dr. Allegretti was particularly interested in monitoring tumor evolution in different cancer settings through clinical follow-up of patients with colorectal, breast, sarcoma, lung, and thyroid carcinomas. Dr. Allegretti has been responsible for all liquid biopsy analysis of cancer patients discussed within his Molecular Tumor Board since 2019. In parallel, he manages several liquid biopsy research projects focused on breast cancer, which he considers an innovative and exciting research area.

    Abstract
    DATE:  March 31, 2020
    TIME:  9:00am PT, 12:00pm ET
     
    HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2 (HER2). While this aggressive breast cancer is highly curable, with 10 year survival rates at an average of >70%, it is also highly prevalent – with this gene mutation being detected in 1 out of every 5 breast cancer cases. In addition to chemotherapy, there are multiple targeted therapies approved for treatment of HER2+ breast cancer. However, HER2+ breast cancer also has a high recurrence rate, increasing the chances of the cancer metastasizing.
     
    In today's presentation, Dr. Allegretti will discuss his clinical research work on HER2+ metastatic breast cancer samples using liquid biopsy (LB) analysis. This study aims to determine feasibility of profiling and tracking over time the molecular behavior of advanced HER2+ breast cancer tumors during drug treatments. Analysis is conducted using two different LB techniques - next-generation sequencing (NGS) and digital PCR (dPCR). Results strongly encourage the integration of LB analysis with genomic assessment from tumor tissues. Together, these complementary techniques may be able to provide compelling evidence to uncover resistance/response mechanisms in the future, potentially yielding valuable clinical information for better cancer management strategies.
     
    Learning Objectives:
    • Investigate advantages of analyzing advanced HER2+ metastatic breast cancer tumor samples with Liquid Biopsy 
    • Demonstrate the complementary nature of dPCR and NGS Liquid Biopsy analysis
    • Illustrate the advantages of combined tissue biopsy and Liquid Biopsy analyses
     
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

     


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    Loading Comments...
    Show Resources
    Attendees
    • See more